[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2004/14899,2004,A1Locationinpatent:Page178
[2]Locationinpatent:schemeortableEmmitte,KyleA.;Andrews,C.Webb;Badiang,JenniferG.;Davis-Ward,RondaG.;Dickson,HamiltonD.;Drewry,DavidH.;Emerson,HollyK.;Epperly,AndreaH.;Hassler,DanielF.;Knick,VictoriaB.;Kuntz,KevinW.;Lansing,TimothyJ.;Linn,JamesA.;MookJr.,RobertA.;Nailor,KristenE.;Salovich,JamesM.;Spehar,GlennM.;Cheung,Mui[BioorganicandMedicinalChemistryLetters,2009,vol.19,#3,p.1018-1021]
[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2004/14899,2004,A1Locationinpatent:Page179
[2]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2005/75465,2005,A1Locationinpatent:Page/Pagecolumn31-32
[3]Locationinpatent:schemeortableEmmitte,KyleA.;Andrews,C.Webb;Badiang,JenniferG.;Davis-Ward,RondaG.;Dickson,HamiltonD.;Drewry,DavidH.;Emerson,HollyK.;Epperly,AndreaH.;Hassler,DanielF.;Knick,VictoriaB.;Kuntz,KevinW.;Lansing,TimothyJ.;Linn,JamesA.;MookJr.,RobertA.;Nailor,KristenE.;Salovich,JamesM.;Spehar,GlennM.;Cheung,Mui[BioorganicandMedicinalChemistryLetters,2009,vol.19,#3,p.1018-1021]
660868-91-7
[1]Locationinpatent:schemeortableEmmitte,KyleA.;Andrews,C.Webb;Badiang,JenniferG.;Davis-Ward,RondaG.;Dickson,HamiltonD.;Drewry,DavidH.;Emerson,HollyK.;Epperly,AndreaH.;Hassler,DanielF.;Knick,VictoriaB.;Kuntz,KevinW.;Lansing,TimothyJ.;Linn,JamesA.;MookJr.,RobertA.;Nailor,KristenE.;Salovich,JamesM.;Spehar,GlennM.;Cheung,Mui[BioorganicandMedicinalChemistryLetters,2009,vol.19,#3,p.1018-1021]
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs).
Journal: Cell cycle (Georgetown, Tex.) 20110915
Title: An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.
Journal: Anti-cancer drugs 20110701
Title: Targeting Plk1 in cutaneous T-cell lymphomas (CTCLs).
Journal: Cell cycle (Georgetown, Tex.) 20110515
Title: Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Journal: Cell cycle (Georgetown, Tex.) 20110415
Title: Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
Journal: Cell cycle (Georgetown, Tex.) 20110415
Title: Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass.
Journal: Carcinogenesis 20100501
Title: Polo-like kinase guides cytokinesis in Trypanosoma brucei through an indirect means.
Journal: Eukaryotic cell 20100501
Title: A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Journal: Leukemia 20090901
Title: Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
Journal: Bioorganic & medicinal chemistry letters 20090315
Title: Discovery of thiophene inhibitors of polo-like kinase.
Journal: Bioorganic & medicinal chemistry letters 20090201
Title: Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
Journal: European journal of pharmacology 20080904
Title: In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
Journal: Molecular cancer therapeutics 20070201
Title: Lansing TJ, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31.
Title: Didier C, et al. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia. Eur J Pharmacol. 2008 Sep 4;591(1-3):102-5.
Title: Ikezoe T, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia. 2009 Sep;23(9):1564-76.
